Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
Détails
ID Serval
serval:BIB_709D8BB6829D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
Périodique
European Urology
ISSN
0302-2838 (Print)
ISSN-L
0302-2838
Statut éditorial
Publié
Date de publication
2007
Volume
52
Numéro
3
Pages
850-858
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
OBJECTIVE: To evaluate the impact of botulinum toxin type A (BoNTA) on health-related quality of life in patients with neurogenic urinary incontinence (UI) using the Incontinence Quality of Life questionnaire (I-QOL).
METHODS: Randomized, double-blind, multicenter, placebo-controlled study involving eight centers across Belgium, France, and Switzerland. Patients (n = 59) with UI due to neurogenic detrusor overactivity (spinal cord injury, n = 53; multiple sclerosis, n = 6) who were inadequately managed on oral anticholinergics received a single dose of BoNTA (200U or 300U, Botox) or placebo. I-QOL scores at screening and after treatment at weeks 2, 6, 12, 18, and 24 were recorded.
RESULTS: Median total and subscale I-QOL scores increased significantly from screening with BoNTA 300U compared with placebo at all time points (p<0.05) and with BoNTA 200U compared with placebo at all time points for total score and the Avoidance Limiting Behavior subscale (p<0.05), and at weeks 2, 6, 12, and 18 (p<0.05), but not 24 for the Psychosocial Impact and Social Embarrassment subscales. Approximately twice as many BoNTA recipients as placebo recipients achieved at least a minimal important difference in total I-QOL score at 2, 6, 12, and 24 wk.
CONCLUSIONS: BoNTA significantly improves UI-associated health-related quality of life in patients with neurogenic UI.
METHODS: Randomized, double-blind, multicenter, placebo-controlled study involving eight centers across Belgium, France, and Switzerland. Patients (n = 59) with UI due to neurogenic detrusor overactivity (spinal cord injury, n = 53; multiple sclerosis, n = 6) who were inadequately managed on oral anticholinergics received a single dose of BoNTA (200U or 300U, Botox) or placebo. I-QOL scores at screening and after treatment at weeks 2, 6, 12, 18, and 24 were recorded.
RESULTS: Median total and subscale I-QOL scores increased significantly from screening with BoNTA 300U compared with placebo at all time points (p<0.05) and with BoNTA 200U compared with placebo at all time points for total score and the Avoidance Limiting Behavior subscale (p<0.05), and at weeks 2, 6, 12, and 18 (p<0.05), but not 24 for the Psychosocial Impact and Social Embarrassment subscales. Approximately twice as many BoNTA recipients as placebo recipients achieved at least a minimal important difference in total I-QOL score at 2, 6, 12, and 24 wk.
CONCLUSIONS: BoNTA significantly improves UI-associated health-related quality of life in patients with neurogenic UI.
Mots-clé
Adult, Aged, Botulinum Toxins, Type A/administration & dosage, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Male, Middle Aged, Neuromuscular Agents/administration & dosage, Quality of Life, Questionnaires, Treatment Outcome, Urinary Bladder, Urinary Bladder, Neurogenic/drug therapy, Urinary Bladder, Neurogenic/psychology
Pubmed
Web of science
Création de la notice
05/11/2014 12:12
Dernière modification de la notice
20/08/2019 14:29
Données d'usage
